Business Wire

Bayer’s FIDELIO-DKD Phase III Study Demonstrated Investigational Drug Finerenone Significantly Reduced Renal and Cardiovascular Outcomes in Patients with Chronic Kidney ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of ...
Nasdaq

Bayer's Finerenone Meets Primary Endpoint In Phase III FIDELIO-DKD Renal Outcomes Study

(RTTNews) - Bayer (BAYZF.PK, BAYRY.PK, BYR.L) announced that the Phase III study FIDELIO-DKD, which is evaluating the efficacy and safety of finerenone versus placebo when added to standard of care ...
Pharmabiz

Phase III FIDELIO-DKD study data shows finerenone has potential to reduce the risk of new onset AFF in patients with CKD and type 2 diabetes

Late-breaking data from a prespecified exploratory analysis of the phase III FIDELIO-DKD study indicate that compared to placebo when added to standard of care, finerenone may significantly reduce the ...
Reuters

Bayer's Finerenone Meets Primary Endpoint In Phase Iii Fidelio-Dkd Renal Outcomes Study

* BAYER - FINERENONE REDUCED COMBINED PRIMARY ENDPOINT OF RISK OF CHRONIC KIDNEY DISEASE PROGRESSION, KIDNEY FAILURE/KIDNEY DEATH VERSUS PLACEBO WHEN ADDED TO STANDARD OF CARE Source text for Eikon: ...
Reuters

Bayer's Finerenone Meets Primary Endpoint In Phase III FIDELIO-DKD Renal Outcomes Study

China's BYD , will acquire a 20% stake in its local distributor Rever Automotive in Thailand, its largest market outside of China where it is an electric vehicle market leader, the companies said ...